Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Notes Payables (2022 - 2025)

Bioregenx (BRGX) has 4 years of Notes Payables data on record, last reported at $1.0 million in Q3 2025.

  • For Q3 2025, Notes Payables rose 19.34% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.0 million, up 19.34%, while the annual FY2024 figure was $883271.0, 135.11% up from the prior year.
  • Notes Payables reached $1.0 million in Q3 2025 per BRGX's latest filing, up from $970117.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $1.0 million in Q3 2025 and bottomed at $12590.0 in Q1 2023.
  • Average Notes Payables over 4 years is $567584.2, with a median of $850152.0 recorded in 2024.
  • Peak YoY movement for Notes Payables: soared 6657.85% in 2024, then increased 3.69% in 2025.
  • A 4-year view of Notes Payables shows it stood at $40970.0 in 2022, then skyrocketed by 816.97% to $375681.0 in 2023, then soared by 135.11% to $883271.0 in 2024, then increased by 18.29% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $1.0 million in Q3 2025, $970117.0 in Q2 2025, and $880796.0 in Q1 2025.